

SELECTED BIBLIOGRAPHY

THYMOSIN ALPHA 1 USE IN CANCER

MELANOMA

Nonclinical Studies:

1. Favalli, C. et al. (1989) *Synergistic effect of thymosin alpha 1 and alpha/beta interferon on NK activity in tumor-bearing mice.* International Journal of Immunopharmacology **11**:443-450.
2. Pica, F., et al. (1998) *High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.* Anticancer Research **18**: 3571-3578.

Clinical Studies:

3. Lopez, M., et al. (1993) *Biological agents and chemotherapy in the treatment of solid tumors.* Third International Symposium on Combination Therapies.
4. Favalli, C. (1993) *Combination therapy in malignant melanoma.* Third International Symposium on Combination Therapies.
5. Lopez, M., et al. (1994) *Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.* Annals of Oncology **5**: 741-746.
6. Rasi, G., et al. (1997) *Immunological changes induced by combined treatment with thymosin alpha 1 and low-dose interferon-alpha after dacarbazine in advanced melanoma.* Melanoma Research **7**: 495.
7. Rasi, G., et al. (1997) *Combined treatment with thymosin alpha 1 and low-dose interferon-alpha after dacarbazine in advanced melanoma.* Melanoma Research **7**: 415.

8. Rasi, G. et al. (2000) *Combined treatment with thymosin alpha 1 and low dose interferon alpha after dacarbazine in advanced melanoma*. *Melanoma Research* **10**: 189 – 192.
9. Rasi G., et al. (2002) *Beneficial effects of infused thymalfasin in melanoma*. *Molecular Therapeutics Symposium, ASCO*.

HEPATOCELLULAR CARCINOMA

Clinical Studies:

10. Stefanini, G., et al. (1998) *Alpha 1 thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience*. *Hepato-Gastroenterology* **45**: 209-215.
11. Li, Z. (2001) *HCC patients treated with TACE combined with thymalfasin – one year follow up*. *Shanghai International Oncology Conference 2001*.
12. Shuqun, C., et al. (2004) *Combination transcatheter hepatic arterial chemoembolization with thymosin alpha 1 on recurrence prevention of hepatocellular carcinoma*. *Hepato-Gastroenterology* **51**: 1445-1447.

PANCREATIC CANCER

Clinical Studies:

13. Ni, Q. Fu, D., Yu, X. Xu, J., Hua, Y., CHEN, w., Zhang, Y. (2001) *Efficacy of thymalfasin on cellular immune function and chemotherapy induced toxicity in pancreatic cancer*. *Proceedings of ASCO, #2630*.

NON-SMALL CELL LUNG CANCER

Nonclinical Studies:

14. Tomazic, V., et al. (1988) *Thymic factor-induced reduction of pulmonary metastases in mice with FSA-1 fibrosarcoma*. Clinical and Experimental Metastasis **6**: 17-25.
15. Garaci, E., et al. (1990) *Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice*. Cancer Immunology and Immunotherapy **32**: 154-160.
16. Mastino, A., et al. (1992) *Combination therapy with thymosin alpha 1 potentiates the antitumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis Lung carcinoma in mice*. Cancer Research **50**: 493-499.
17. Moody, T., et al. (1993) *Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo*. Cancer Research **53**: 5214-5218.
18. Moody, T., et al. (1998) *Thymosin alpha 1 prevents lung carcinogenesis*. FASEB Journal **12**: A1457.
19. Moody, T. et al. (2000) *Thymosin alpha 1 is chemopreventive for lung adenoma formation in A/J mice*. Cancer Letters **155**: 121-127.

Clinical Studies:

20. Dillman, R.O., et al. (1982) *Phase I trials of thymosin fraction 5 and thymosin alpha 1*. Journal of Biological Response Modifiers **1**: 35-41.
21. Schulof, R., et al. (1982) *The immunopharmacology and pharmacokinetics of thymosin alpha 1 administration in man: a prototypic thymic hormone efficacy trial in patients with lung cancer*, in Current concepts in human immunology and cancer immunodulation, B. Serrou, et al., Editors. Elsevier Biomedical Press: Amsterdam. p. 545-52.

22. Dillman, R.O., et al. (1983) *In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 and thymosin alpha 1*. Journal of Biological Response Modifiers **2**: 139-150.
23. Schulof, R.S., et al. (1984) *An evaluation of two different schedules of synthetic thymosin alpha 1 administration in patients with lung cancer: preliminary results*, in Thymic hormones and Lymphokines, A. Goldstein, Editor. Plenum Press: New York. p. 601-613.
24. Schulof, R.S., et al. (1985) *A randomized trial to evaluate the immunorestorative properties of synthetic thymosin alpha 1 in patients with lung cancer*. Journal of Biological Response Modifiers **4**: 147-158.
25. Schulof, R.S., et al. (1985) *Immunorestorative and therapeutic effects of synthetic thymosin alpha 1 in patients with lung cancer*, in Serono Symposium on Thymic Factor Therapy, J.R. Hobbs, Editor. Academic Press: New York. p. 301-308.
26. Schulof, R.S., et al. (1985) *T-cell abnormalities after mediastinal irradiation for lung cancer. The in vitro influence of synthetic thymosin alpha 1*. Cancer **55**: 974-983.
27. Dillman, R.O., et al. (1987) *Phase II trial of thymosin fraction 5 and thymosin alpha 1*. Journal of Biological Response Modifiers **6**: 263-267.
28. Lopez, M., et al. (1992) *Thymosin alpha 1 and alpha interferon with cisplatin and etoposide in advanced non-small-cell lung cancer: a phase II study*, in Second International Symposium on Combination Therapies. Sicily, Italy.
29. Garaci, E., et al. (1995) *Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin alpha 1 and interferon alpha2a*. European Journal of Cancer **31A**: 2403-2405.
30. Asbell, S.O., et al. (1996) *Phase III RTOG double blind lung cancer trial of XRT and subsequent thymosin or placebo*. Proceedings of ASCO.

31. Salvati, F., et al. (1996) *Combined treatment with thymosin alpha 1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase II controlled trial*. *Anticancer Research* **16**: 1001-1004.
32. Chen, J. et al. (2000) *Thymosin alpha 1 positively alters quality of life in chemotherapy treated patients*. *Proceedings of ASCO*.
33. Liu, X. et al. (2003) *Thymalfasin for the protection of chemotherapy-induced neurotoxicity: a pilot study*. *Proceedings of ASCO*.

BREAST CANCER

Nonclinical Studies:

34. Moody, T. W., et al. (2002) *Thymosin alpha 1 inhibits mammary carcinogenesis in Fisher rats*. *Peptides* **23**: 1011 – 1014.

Clinical Studies:

35. Terzoli, E., et al. (1992) *Advanced breast cancer treatment with thymosin alpha 1, IFN alpha and epirubicin: preliminary results*. *Second International Symposium on Combination Therapies*.
36. Terzoli, E., et al. (1992) *Combined treatment of advanced breast cancer with epirubicin, thymosin alpha 1 and alpha interferon*. *American Society of Clinical Oncology* **11**: 69.

COLORECTAL CANCER

Nonclinical Studies:

37. Rasi, G., et al. (1994) *Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats*. *International Journal of Cancer*. **57**: 701-705.

38. Silecchia, G., et al. (1995) *Effectiveness of intraperitoneal combination therapy on experimental liver metastases from colorectal carcinoma*. *Anticancer Research* **15**: 1807.
39. Silecchia, G, et al. (1999) *Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery*. *Cancer Immunol. Immunother.* **48**: 172-178.

HEAD AND NECK CANCER

Clinical Studies:

40. Wolf, G.T., et al. (1989) *Prospective randomized trial of thymosin alpha 1 immune reconstitution in patients with advanced head and neck squamous carcinoma: 5 year results*. *Proceedings of the American Association for Cancer Research* **30**: 261.

GASTRIC CANCER

Clinical Studies:

41. Basso, N., et al. (1992) *Adjuvant chemoimmunotherapy in gastric cancer patients: pilot study-phase II. Preliminary result*. *Second International Symposium on Combination Therapies*.

LEUKEMIA

Nonclinical Studies:

42. Garaci, E., et al. (1993) *Antitumor effect of thymosin alpha-1/interleukin-2 or thymosin -1/interferon following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells*. Journal of Immunotherapy **13**: 7-17.

Clinical Studies:

43. Venditti, A., et al. (1993) *Combination therapy with biological factors and differentiating agents in the treatment of malignant haemopathy*. Third International Symposium on Combination Therapies.
44. Venditti, A., et al. (1993) *Biological response modifiers and differentiating agents in myelodysplastic syndromes*, in Combination therapies I, A.L. Goldstein and E. Garaci, Editors. Plenum Press: New York. p. 171-177.

REVIEWS

Nonclinical Studies:

45. Ishitsuka, H., et al. (1983) *Protective activity of thymosin alpha 1 against tumor progression in immunosuppressed mice*. Advances in Experimental Medicine and Biology **166**: 89-100.

Clinical Studies:

46. Baskies, A.M., et al. (1982) *Thymosin alpha 1: first clinical trial and comparison with thymosin fraction 5*, in Current Concepts in Human Immunology and Cancer Immunomodulation, B. Serrou, et al., Editors. Elsevier Biomedical Press: Amsterdam. p. 567-574.
47. Smalley, R., et al. (1984) *The thymosins - preclinical and clinical studies with fraction 5 and alpha 1*. Cancer Treatment Reviews **11**: 69-84.

48. Schulof, R.S. (1985) *Thymic peptide hormones: basic properties and clinical applications in cancer*. CRC Critical Reviews in Oncology and Hematology **3**: 309-376.
49. Garaci, E, et al. (2000) *Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application*. International Journal of Immunopharmacology **22**: 1067-1076.
50. Garaci, E, et al. (2003) Garaci, E., et al. *Thymosin alpha 1 in combination with cytokines and chemotherapy for the treatment of cancer*. International Immunopharmacology **3**: 1145-1150
51. Rasi, G., et al. (2003) *Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma*. International Immunopharmacology **3**: 1169-1176